China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine Ltd and Shenzhen XtalPi (QuantumPharm, HKG: 2228). These collaborations will integrate artificial intelligence (AI) into the field of innovative drug research and development. Under the agreements, CSPC will utilize its drug R&D expertise alongside the leading AI technology platforms of Insilico and XtalPi to enhance the efficiency and success rate of new drug screening, focusing on strategic product types with high clinical demand.
Insilico: Generative AI in Drug Discovery and Development
Insilico, a biotech company driven by generative AI, is connecting biology, chemistry, and clinical trials analysis through next-generation AI systems. The company has developed AI platforms that employ deep generative models, reinforcement learning, transformers, and other advanced machine learning techniques for novel target discovery and the generation of drug candidates with specific molecular structures and desired properties. Insilico is committed to developing breakthrough solutions to address unmet medical needs in areas such as cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.
XtalPi: AI and Robotics in Life Sciences and New Materials Industries
XtalPi, an innovative technology company founded by MIT scientists in 2014, is powered by AI and robotics. Dedicated to driving intelligent and digital transformation in the life science and new materials industries, XtalPi offers a range of innovative technology solutions, services, and products. With expertise in quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi serves the biopharmaceutical, chemical, new energy, and new materials industries globally.-Fineline Info & Tech
